Itau Unibanco Holding S.A. Fate Therapeutics Inc Transaction History

Itau Unibanco Holding S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$9.86 - $23.83 $187 - $452	-19 Reduced 7.76%	226 $2,000
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $889 - $2,119	-50 Reduced 16.95%	245 $6,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $356 - $723	12 Added 4.24%	295 $11,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $191 - $257	4 Added 1.43%	283 $17,000
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $474 - $765	8 Added 2.95%	279 $17,000
Q2 2021 Aug 17, 2021	BUY	$67.25 - $92.52 $18,224 - $25,072	271 New	271 $24,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.